Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit.
Sphere Fluidics Limited
Sphere Fluidics is commercialising novel products and R&D services in the area of single cell analysis and characterisation.
Telephone: +44 (0)1223 628890
Address :
The McClintock Building, Suite 7, Ground Floor Granta Park, Great Abington Cambridge
Post Code: CB21 6GP
Country: United Kingdom
Website: http://www.spherefluidics.com
Membership Type: Corporate 21-50
Sphere Fluidics Limited has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area. Sphere Fluidics' technology enables: study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains. Uniquely, these systems enable the study of different, large biomolecules that interact with or are secreted by single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology.
There are no Products & Services to display
Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows.
17-05-2021
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.
20-07-2020
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise for Innovation. The award recognises the Company’s excellence in patenting, developing and globally commercialising single cell analysis systems for biotherapeutic discovery.
21-04-2020
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing.
14-02-2020
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leading supplier of intelligent laboratory automation solutions, today announced the optimization of the Cyto-Mine® Single Cell Analysis System through integration with PAA’s automated plate handler, S-LAB™. The addition of S-LAB...
05-11-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.
09-09-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to...
27-08-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth.
21-08-2019
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project - featuring technology from Sphere Fluidics and Horizon Discovery Group - to optimise the development of novel therapeutics.
19-06-2019
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment.
10-06-2019
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organisation (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
15-04-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites.
26-03-2019
Oxford Genetics and Sphere Fluidics announce a multi-partner collaboration to expedite the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.
25-02-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed a $2 million (circa £1.5 million) investment round.
29-01-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.
15-01-2019
Sphere Fluidics, a company commercialising single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System.
17-09-2018
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB).
14-08-2018
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has today announced the expansion of its international commercial operations.
30-01-2018
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, and Geneva Biotech, an EMBL spin-out developing world-class viral and non-viral DNA delivery systems, have received a €1.6 million grant from Eurostars. The funding will be used to develop large DNA cargo gene delivery and genome engineering systems.
27-11-2017
Pages
There are no events to display
There are no jobs to display
No Blog articles found
